John J. Boniface sold $728k of SERA
Chief Scientific Officer at SERA PROGNOSTICS, INC.. 77,136 shares at an average of $9.44, traded Mar 27, 2024, filed Mar 28, 2024.
Score components
- +15RoleOfficer
- +21Trade size$728k at market
- +20Share of holdings soldSold 54% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001534969-24-000073, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -3,753 | $9.62 | $36k | 139,771 | Mar 28, 2024 |
| Mar 27, 2024 | MOption exercise Class A Common Stock10b5-1 | +48,909 | $0.91 | $45k | 188,680 | Mar 28, 2024 |
| Mar 27, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -48,909 | $9.62 | $471k | 139,771 | Mar 28, 2024 |
| Mar 28, 2024 | MOption exercise Class A Common Stock10b5-1 | +24,474 | $0.91 | $22k | 164,245 | Mar 28, 2024 |
| Mar 28, 2024 | SOpen-market sale Class A Common Stock10b5-1 | -24,474 | $9.04 | $221k | 139,771 | Mar 28, 2024 |
| Mar 27, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -48,909 | $0.00 | $0 | 24,474 | Mar 28, 2024 |
| Mar 28, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -24,474 | $0.00 | $0 | 0 | Mar 28, 2024 |
Related signals
Other insiders at SERA PROGNOSTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | SERA PROGNOSTICS, INC. | Dyaarl Lee Anderson Jr. Chief Commercial Officer | $3,600 1,800 shares | -2% | |
| 30Weak | SERA PROGNOSTICS, INC. | Tiffany Eul Davis Inglis Chief Medical Officer | $972 486 shares | -1% | |
| 30Weak | SERA PROGNOSTICS, INC. | Benjamin Jackson General Counsel | $4,380 2,190 shares | -1% | |
| 40Moderate | SERA PROGNOSTICS, INC. | Zhenya Lindgardt Chief Executive Officer | $14k 7,022 shares | -1% | |
| 46Moderate | SERA PROGNOSTICS, INC. | Zhenya Lindgardt Chief Executive Officer | $40k 20,139 shares | -2% | |
| 37Weak | SERA PROGNOSTICS, INC. | Austin Aerts Chief Financial Officer | $4,094 2,037 shares | -1% | |
| 30Weak | SERA PROGNOSTICS, INC. | Dyaarl Lee Anderson Jr. Chief Commercial Officer | $9,525 4,739 shares | -6% | |
| 30Weak | SERA PROGNOSTICS, INC. | Tiffany Eul Davis Inglis Chief Medical Officer | $728 362 shares | -0% | |
| 30Weak | SERA PROGNOSTICS, INC. | Benjamin Jackson General Counsel | $4,380 2,179 shares | -1% | |
| 40Moderate | SERA PROGNOSTICS, INC. | Zhenya Lindgardt Chief Executive Officer | $14k 6,990 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.